Beside, Arguilar-Rojas and colleagues found out that Busrelin, a GnRH agonist, regulates RhoA activity in MDA-MB-231 breast cancer cells thereby decreasing invasiveness54. This evidence concerns the gene RHOA and breast carcinoma.